Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $54.8 million initial public offering by Aeglea BioTherapeutics, Inc. Aeglea’s common stock is listed on the NASDAQ Global Market under the symbol “AGLE.”

UBS Investment Bank, BMO Capital Markets, Wells Fargo Securities, Needham & Company acted as joint book-running managers. Based in Austin, Texas, Aeglea is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. The company, led by David G. Lowe, Charles N. York, Ann M. Lowe, Scott W. Rowlinson and Henry L. Hebel, was founded in 2013. The Davis Polk corporate team included partner Bruce K. Dallas (Picture), counsel Jeffrey Gould and associate Keerthika Melissa Subramanian. The tax team included partner Rachel D. Kleinberg and associate Alexander Wu. The intellectual property and technology team included associates Michelle Gross and Jason J. Bang. Counsel Marcie A. Goldstein provided FINRA advice. Involved fees earner: Bruce Dallas - Davis Polk & Wardwell; Jeffrey Gould - Davis Polk & Wardwell; Keerthika Melissa Subramanian - Davis Polk & Wardwell; Rachel Kleinberg - Davis Polk & Wardwell; Alexander Wu - Davis Polk & Wardwell; Michelle Gross - Davis Polk & Wardwell; Jason Bang - Davis Polk & Wardwell; Marcie Goldstein - Davis Polk & Wardwell;